Combination Therapeutic Effect of Psoralen and Paclitaxel-Loaded Superparamagnetic Iron Oxide Nanoparticles for the Treatment of Triple-Negative Breast Cancer

Purpose

To overcome dose-limiting toxicity and paclitaxel (PTX) resistance in triple-negative breast cancer (TNBC) therapy, as well as the asynchronous in vivo biodistribution of PTX and psoralen (PSO) combination regimens, we developed a highly biocompatible, magnetically targeted nano-co-delivery system.